The goal of this clinical trial is to compare the size of myocardial infarct between
evolocumab and control groups in patients with ST segment elevation myocardial infarction who
undergoing primary percutaneous coronary intervention(PCI). All study participants will
undergo a cardiac MRI 4 weeks after primary reperfusion. The evolocumab group will receive
420 mg before PCI via subcutaneous injection.
Phase:
Phase 3
Details
Lead Sponsor:
Sejong General Hospital
Collaborators:
Catholic University of Korea Eunpyeong St. Mary's Hospital Chonnam National University Hospital Daegu Catholic University Medical Center Inje University Ilsan Paik Hospital National Health Insurance Service Ilsan Hospital Samsung Medical Center